• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthabortion

Texas judge says 3 states can again challenge abortion pill access nationwide

By
Geoff Mulvihill
Geoff Mulvihill
,
Lindsay Whitehurst
and
The Associated Press
The Associated Press
Down Arrow Button Icon
January 17, 2025, 5:28 AM ET
They aim to roll back federal rules and make it harder for people across the U.S. to access the abortion drug mifepristone.
They aim to roll back federal rules and make it harder for people across the U.S. to access the abortion drug mifepristone.Bill Grenblatt—Liaison

The Texas judge who previously halted approval of the nation’s most common method of abortion ruled Thursday that three states can move ahead with another attempt to roll back federal rules and make it harder for people across the U.S. to access the abortion drug mifepristone.

Recommended Video

Idaho, Kansas and Missouri requested late last year to pursue the case in federal court in Amarillo, Texas, after the U.S. Supreme Court issued a narrow ruling finding that abortion opponents who first filed the case lacked the legal right to sue.

The only federal judge based in Amarillo is Matthew Kacsmaryk, a nominee of former President Donald Trump who in recent years ruled against the Biden administration on several issues, including immigration and LGBTQ protections.

The states want the federal Food and Drug Administration to prohibit telehealth prescriptions for mifepristone and require that it be used only in the first seven weeks of pregnancy instead of the current limit of 10 weeks. They also want to require three in-person doctor office visits instead of none to get the drug.

That’s because, the states argue, efforts to provide access to the pills “undermine state abortion laws and frustrate state law enforcement,” according to court documents.

Meanwhile, Kacsmaryk said they shouldn’t be automatically discounted from suing in Texas just because they’re outside the state.

The American Civil Liberties Union said Thursday that the case should have been settled when the U.S. Supreme Court unanimously preserved access to mifepristone last year, where the justices issued a narrow ruling finding that abortion opponents who first filed the case lacked the legal right to sue.

Kacsmaryk’s decision “has left the door open for extremist politicians to continue attacking medication abortion in his courtroom,” the ACLU said.

The ruling comes days before Trump begins his second term as president, so his administration will likely be representing the FDA in the case. Trump has repeatedly said abortion is an issue for the states, not the federal government, though he’s also stressed on the campaign trail that he appointed justices to the Supreme Court who were in the majority when striking down the national right to abortion in 2022.

In the years since, abortion opponents have increasingly targeted abortion pills, largely due to most U.S. abortions being carried out using drugs rather than through surgical procedures. So far, at least four states — Indiana, Missouri, New Hampshire and Tennessee — have seen Republicans introduce bills aimed at banning pills. None take the same approach as Louisiana, which last year classified the drugs as controlled dangerous substances.

Previously, Kacsmaryk sided with a group of anti-abortion doctors and organizations that wanted the FDA to be forced to rescind entirely its approval of mifepristone in 2000.

Yet the states are pursuing a narrower challenge. Rather than target the approval entirely, they sought to undo a series of FDA updates that have eased access.

But while the states’ leaders are pushing to severely limit access to the drugs, voters in Missouri sent a different message in November when they approved a ballot measure to undo one of the nation’s strictest bans. In Idaho, abortion is banned at all stages of pregnancy. In Kansas, abortion is generally legal up until the 22nd week of pregnancy.

Across the U.S., 13 states under Republican legislative control bar abortion at all stages of pregnancy, with some exceptions, and four more ban it after the first six weeks — before women often know they’re pregnant.

Some Democratic-controlled states have adopted laws seeking to shield from investigations and prosecutions the doctors who prescribe the pills via telehealth appointments and mail them to patients in states with bans. Those prescriptions are a major reason a study found that residents of states with bans are getting abortions in about the same numbers as they were before the bans were in place.

Mifepristone is usually used in combination with a second drug for medication abortion, which has accounted for more than three-fifths of all abortions in the U.S. since the Supreme Court’s ruling overturning Roe v. Wade.

The drugs are different than Plan B and other emergency contraceptives that are usually taken within three days after possible conception, weeks before women know they’re pregnant. Studies have found they’re generally safe and result in completed abortions more than 97% of the time, which is less effective than procedural abortions.

Join us at the Fortune Workplace Innovation Summit May 19–20, 2026, in Atlanta. The next era of workplace innovation is here—and the old playbook is being rewritten. At this exclusive, high-energy event, the world’s most innovative leaders will convene to explore how AI, humanity, and strategy converge to redefine, again, the future of work. Register now.
About the Authors
By Geoff Mulvihill
See full bioRight Arrow Button Icon
By Lindsay Whitehurst
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Economy
America's $38 trillion national debt 'exacerbates generational imbalances' with Gen Z and millennials paying the price, warns think tank
By Eleanor PringleDecember 16, 2025
2 days ago
placeholder alt text
Success
As millions of Gen Zers face unemployment, McDonald's CEO dishes out some tough love career advice for navigating the market: ‘You've got to make things happen for yourself’
By Preston ForeDecember 16, 2025
1 day ago
placeholder alt text
Innovation
An MIT roboticist who cofounded bankrupt Roomba maker iRobot says Elon Musk's vision of humanoid robot assistants is 'pure fantasy thinking'
By Marco Quiroz-GutierrezDecember 16, 2025
1 day ago
placeholder alt text
AI
IBM, AWS veteran says 90% of your employees are stuck in first gear with AI, just asking it to ‘write their mean email in a slightly more polite way’
By Marco Quiroz-GutierrezDecember 16, 2025
1 day ago
placeholder alt text
Politics
Exclusive: After citations against Elon Musk’s Boring Company were suddenly withdrawn, federal regulators are now investigating Nevada OSHA
By Jessica MathewsDecember 16, 2025
1 day ago
placeholder alt text
Banking
Trump turns on CBS, Kushner pulls out and Paramount's hostile bid for Warner Bros. shows signs of collapse
By Eva RoytburgDecember 16, 2025
1 day ago

Latest in Health

SuccessMillionaires
Tech CEO Bryan Johnson says he’ll make humans immortal by 2039—first he just needs to sort out ‘buggy’ issues like ‘mistakenly causing cancer’
By Orianna Rosa RoyleDecember 17, 2025
13 hours ago
Johnson
PoliticsHealth Insurance
Vulnerable Republican blasts choice to send health insurance spiking as ‘political malpractice’
By Kevin Freking, Lisa Mascaro and The Associated PressDecember 16, 2025
1 day ago
FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
2 days ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
3 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
4 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
4 days ago